Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could bright light fix Parkinson's sleep troubles?

NCT ID NCT02909192

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether bright light therapy can help with sleep and alertness issues in people with Parkinson's disease. Researchers will measure sleep quality, daytime sleepiness, and other non-motor symptoms in 65 participants. The goal is to see if light exposure can improve the body's internal clock and reduce these disabling symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Light therapy device
What this could lead to
If it works, this could offer a simple, drug-free way to improve sleep and daytime alertness for people with Parkinson's disease.
What could go wrong
This is a small, early-stage study with only 65 participants. The results may not apply to everyone, and bright light therapy might not work for all sleep problems in Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Dec 2016

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank Criteria 2. PD Hoehn and Yahr stage 2-4 3. Pittsburgh Sleep Quality Index (PSQI) score ≥ 5 4. Treatment with levodopa and/or dopamine agonist; adjunctive PD medications will be allowed 5. Stable dose of PD medications for at least 4 weeks prior to the study screening. Exclusion criteria: 1. Atypical or secondary forms of parkinsonism 2. Co-existent significant sleep apnea (as assessed by polysomnography- derived apnea/hypopnea index ≥15 events/hr of sleep) 3. Co-existent restless legs syndrome (RLS), as assessed by the International Classification of Sleep Disorders (ICDS) diagnostic criteria for RLS 4. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score of ≤ 26 5. Presence of depression defined as the Beck Depression Inventory (BDI) score \>14 6. Untreated hallucinations or psychosis (drug-induced or spontaneous) 7. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible 4 weeks after the taper is completed 8. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) antidepressants, unless the participant has been on a stable dose for at least 3 months prior to the screening 9. Use of medications known to affect melatonin secretion, such as lithium, alpha- and beta-adrenergic antagonists 10. Shift work, currently or within the prior 3 months 11. Travel through ≥ 2 time zones within 60 days prior to study screening 12. Hematocrit \<32 mm3 13. Pre-existing glaucoma/retinal disease contraindicated for light therapy (LT) 14. Dense cataracts 15. Use of medications known to photosensitize retinal tissue (phenothiazines, chloroquine, amiodarone, St. John's Wort) 16. Unstable/serious medical illness. 17. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.